FINWIRES · TerminalLIVE
FINWIRES

BridgeBio Posted Q2 Revenue Beat, but Faces Higher Near-Term Launch Opex, Morgan Stanley Says

By

BridgeBio Pharma (BBIO) posted a Q2 revenue beat, while facing higher near-term launch opex and a wider 2026-27 loss, Morgan Stanley said in a Tuesday research report.

New drug applications for the company's three late-stage programs, including the BBP-418 candidate and encaleret, have been filed with the US Food and Drug Administration, and two of the applications are in the priority review stage with hard Prescription Drug User Fee Act dates, analysts wrote.

The company faces risks related to pricing pressure on Attruby to treat cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis, slower frontline share gains, and potential regulatory setbacks, according to the note.

The brokerage said it now expects a 2026 loss of $2.90 from $2.61 earlier. For 2027, it expects a loss of $0.55 from $0.46 previously.

The brokerage reiterated its overweight rating on the stock and adjusted its price target to $97 per share from $98.

Price: $85.10, Change: $+0.42, Percent Change: +0.50%

Related Articles

Wire

Fermi Signs First Binding Lease Agreement at Project Matador in Texas; Shares Rise After Hours

Fermi (FRMI) said late Monday it has signed its first binding customer lease at its Project Matador campus in Texas, a deal expected to generate about $6.5 billion over its initial 15-year term for the first phase.The lease between Fermi's subsidiary Fermi Campus 1 and TensorWave TEX1, a unit of TensorWave, covers a facility supported by 222 megawatts of total power once the final delivery phase begins.The agreement includes expansion rights for two additional data centers that would bring the partnership to more than 650 MW if exercised.Project Matador's first power is targeted for 2026, with construction already underway and permits secured for about 6 GW of the planned 17-GW campus.Fermi shares jumped 19% in after-hours trading.

$FRMI
Wire

Everpure Secures Second Hyperscaler Design, Supply Agreement; Shares Rise After Hours

Everpure (P) secured a second design and supply contract with an undisclosed top-five hyperscaler.The first contract was announced in late 2024 and uses Everpure's advanced software-powered DirectFlash technology to optimize hyperscale storage.The latest contract will be a "significant contributor to future revenue" starting in fiscal 2028, the company said Monday in a statement.Everpure shares rose 7.7% in after-hours trading.

$P
Wire

Upwork Q2 Adjusted Earnings Rise, Revenue Declines; Shares Fall After-Hours

Upwork (UPWK) reported Q2 non-GAAP earnings late Monday of $0.41 per diluted share, up from $0.35 a year earlier.Analysts polled by FactSet expected $0.34.Revenue for the quarter ended June 30 was $191.7 million, down from $194.9 million a year earlier.Analysts expected $189.9 million.The company expects Q3 non-GAAP EPS of $0.31 to $0.33 on revenue of $176 million to $184 million. Analysts expect $0.41 and $193.8 million, respectively.The company now expects 2026 non-GAAP EPS of $1.38 to $1.43 on revenue of $730 million to $750 million. It previously expected non-GAAP EPS of $1.50 to $1.55 on revenue of $760 million to $790 million.Analysts expect $1.54 and $776.0 million, respectively.Upwork shares fell over 21% in after-hours trading.

$UPWK
BridgeBio Posted Q2 Revenue Beat, but Faces Higher Near-Term Launch Opex, Morgan Stanley Says | FINWIRES